Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Controlled release formulation|
|Abstract:||A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.|
|Inventor(s):||Miller; Ronald B. (Basel, CH), Leslie; Stewart T. (Cambridge, GB2), Malkowska; Sandra T. A. (Cambridgeshire, GB2), Smith; Kevin J. (Cambridge, GB2), Wimmer; Walter (Limburg, DE), Winkler; Horst (Linter, DE), Hahn; Udo (Nentershausen, DE), Prater; Derek A. (Cambridge, GB2)|
|Assignee:||Euro-Celtique, S.A. (Luxembourg, LU)|
Patent Claim Types:|
see list of patent claims
|Composition; Formulation; Compound; Dosage form;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||1527775||<disabled in preview>|
|European Patent Office||1504758||<disabled in preview>|
|European Patent Office||1504757||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.